RT - Article
SR - Electronic
T1 - 
SP - 2024-01-30
DO - 10.2174/0113816128262498231122072050
A1 - , 
A1 - , 
A1 - , 
A1 - , 
A1 - , 
A1 - , 
A1 - , 
A1 - , 
A1 - , 
A1 - , 
A1 - , 
YR - 2023
UL - https://repo.bashgmu.ru/publication/2869
AB - Introduction: Renal cancer ranks 10th in the mortality structure of the Russian Federation. The introduction of checkpoint inhibitors has changed the paradigm of treatment of patients with malignant neoplasms. Methods: Data from clinical trials have shown good progression-free median and median overall survival. Each cancer center has been accumulating its own experience in treating patients with renal cell cancer by app-lying modern target drugs and immunotherapy. Results: In routine clinical practice, oncologists do not get the results that have been demonstrated in clinical trials when evaluating the effectiveness of the therapy. Conclusion: In this single-center clinical study, we discuss the results of using nivolumab as mono-therapy and the combination of nivolumab with ipilimumab in metastatic renal parenchyma cancer patients. © 2023 Bentham Science Publishers.